Targeting cell fate regulators to treat rare skin cancer

Merkel cell carcinoma (MCC) is a highly aggressive skin cancer with limited treatment options. Scientists at the Research Institute of Molecular Pathology (IMP) in Vienna have now identified an epigenetic factor – the protein LSD1 – that may prove to be a novel and effective therapeutic entry point in MCC. The study is published in the current issue of the journal EMBO Molecular Medicine.